Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on MeiraGTx (MGTX) to $18 from $20 and keeps an Outperform rating on the shares. The firm adjusted targets for its small-to-mid cap biotechnology coverage as it analyzed Q2 catalysts. However, the firm acknowledges that stocks in the group are moving on longer-horizon theses so it also looked at all FY26 catalysts, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX:
- MeiraGTx’s AI Push Raises Operational, Regulatory and Data Privacy Risk Concerns
- MeiraGTx price target lowered to $26 from $30 at Piper Sandler
- MeiraGTx price target raised to $16 from $14 at BofA
- MeiraGTx Highlights Breakthrough Gene Therapy and Strategic Alliances
- MeiraGTx announces FDA breakthrough therapy designation for AAV2-hAQP1